Skip to main content

What the FDA labels say about taking them together

Cholestyramine and odevixibat

Odevixibat's FDA label of December 29, 2025 names cholestyramine in its drug interactions section; the cholestyramine label PlainMeds reads does not name odevixibat. The odevixibat label: “DRUG INTERACTIONS 7.1 Bile Acid Binding Resins Administer bile acid binding resins at least 4 hours before or 4 hours after administration of BYLVAY.”

Check it at the source: the cholestyramine FDA label on DailyMed (effective August 20, 2026, AiPing Pharmaceutical, Inc.); the odevixibat FDA label on DailyMed (effective December 29, 2025, Ipsen Biopharmaceuticals, Inc.).

What does the cholestyramine label say about odevixibat?

Cholestyramine's label (effective August 20, 2026) does not name odevixibat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Cholestyramine), AiPing Pharmaceutical, Inc., effective August 20, 2026 (SPL set 214ea05f-de81-4026-9df9-4ce3820668ee), via openFDA; the full label on DailyMed

What does the odevixibat label say about cholestyramine?

Odevixibat label, drug interactions

DRUG INTERACTIONS 7.1 Bile Acid Binding Resins Administer bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol) at least 4 hours before or 4 hours after administration of BYLVAY [see Dosage and Administration (2.3) ].

Source: FDA drug label (Bylvay), Ipsen Biopharmaceuticals, Inc., effective December 29, 2025 (SPL set 0935cd31-3251-4a0a-ac23-25ca4be12be9), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

15Cholestyramine generic labelers
0Odevixibat generic labelers
CholestyramineOdevixibat
Labeled forHigh cholesteroln/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.834 per packet Cholestyramine packetn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?